Rentokil can win rat race after Terminix stumbles, says broker
Rentokil Initial PLC (LSE:RTO) could be poised for a recovery after years of disruption linked to its acquisition of US business Terminix, according to Panmure Liberum. The broker initiated coverage with a 'buy' rating and a 563p price target, saying the FTSE 100 group is the world's largest pest control company, with around 20% global market share and about 25% of the North American market, giving it scale advantages in an industry benefiting from long-term growth drivers including urbanisation, climate change and stricter hygiene standards.
RTO vs. ULS: Which Stock Should Value Investors Buy Now?
Investors with an interest in Business - Services stocks have likely encountered both Rentokil Initial PLC (RTO) and UL Solutions Inc. (ULS). But which of these two stocks offers value investors a better bang for their buck right now?
Inside Amazon: 12 employees describe life under layoffs, AI pressure, and 5-day RTO
Amazon's "Day 1" culture primes employees for constant change. And there's been plenty of it lately: a five-day return-to-office mandate, an AI push, and mass layoffs.
Rentokil Initial plc (RTO) Q1 2026 Sales/Trading Call Transcript
Rentokil Initial plc (RTO) Q1 2026 Sales/Trading Call Transcript
European stocks set for another mixed open as Iran peace efforts remain unclear
European stocks are expected to open in mixed territory as investors assess a confused picture of where the Iran war and peace talks are headed.
Rentokil Initial (NYSE:RTO) versus VCI Global (NASDAQ:VCIG) Financial Analysis
VCI Global (NASDAQ: VCIG - Get Free Report) and Rentokil Initial (NYSE: RTO - Get Free Report) are both business services companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk. Analyst Ratings This is a summary of
Rentokil 2025 Earnings: Looking Beyond The Market's Advance Praise
Rentokil Initial plc (RTO) shows stabilization in 2025, with North America organic growth improving and streamlining efforts beginning to yield results. RTO's recurring significant earnings adjustments and complex reporting continue to obscure true underlying performance, justifying a valuation discount. Leverage remains elevated at 7.5x free cash flow, and although free cash flow covers the dividend, the balance sheet is not robust.
Rentokil: A Bug Business With Long-Term Bite
Rentokil (RTO) offers a more attractive valuation and diversified growth profile than peer Rollins, trading at a significant discount despite similar growth drivers. RTO reported FY'25 revenues of $6.91B (+3.8% YoY), with organic growth, margin expansion, and strong free cash flow supporting deleveraging and investment-grade credit ratings. Industry tailwinds, operational efficiencies, and a robust M&A pipeline underpin expectations for mid-to-high single-digit EPS growth and margin improvement toward 20%+ by 2027.
Rentokil Initial plc (RTO) Q4 2025 Earnings Call Transcript
Rentokil Initial plc (RTO) Q4 2025 Earnings Call Transcript
Rentokil jumps as US pest control momentum improves
Shares in Rentokil Initial PLC jumped 9.2% to 464.6p on Thursday as the pest control giant reported full-year results that met or beat market expectations, helped by improving momentum in North America. Revenue from continuing operations rose 4.4% to $6.9 billion and adjusted operating profit climbed 5.4% to $1.1 billion, both in line with the $6.9 billion City analyst consensus.
Rentokil Initial Reports Higher Revenue Amid Leadership Transition
The pest-control, hygiene and workwear-services provider's revenue climbed 2.6% organically in 2025.
Roquefort Therapeutics to acquire cancer drug licence in £32m RTO deal and raise £8.5m
Roquefort Therapeutics PLC (LSE:ROQ),a biotech company currently valued at less than £1.5 million, is set to be transformed into a clinical-stage oncology business after announcing the £32 million acquisition of an exclusive worldwide licence to a promising cancer drug alongside a £8.5 million fundraise. The company is acquiring the rights to AO-252, an orally administered small molecule drug targeting TACC3, a protein that is over-expressed in many aggressive tumours, from Coiled Therapeutics, a spin-out of A2A Pharma Pharmaceuticals.
